▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #250 by analyst upside · 2026-09-14
CABA
Cabaletta Bio, Inc.
Healthcare · Market Cap $463M · P/E 0x
ANALYST PRICE TARGET
+385.3%
implied upside to consensus target
Current Price $2.73
Consensus Target $13.25
Bull Target $30.0
Bear Target $3.0
Analysts Covering 8
ANALYST CONSENSUS - BUY
Strong Buy
1
Buy
6
Hold
2
Sell
0
52-Week Low $1.82
52-Week High $4.23
YTD Return +23.5%
FUNDAMENTALS
Market Cap $463M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-1.38
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $1.82
52-Week High $4.23
Current Price $2.73
Bear Target $3.0
Bull Target $30.0
● Now $2.73 ● Target $13.25
TRADING DATA
Avg Volume 5.0M
YTD Return +23.5%
Analyst Count 8
Consensus Buy
Upside to Target +385.3%
Last Updated 2026-09-14

ANALYST SUMMARY

Cabaletta Bio, Inc. (CABA) is currently trading at $2.73 with a Wall Street consensus price target of $13.25, implying potential upside of 385.3% over the next 12 months. 8 analysts currently cover CABA, with a consensus rating of Buy - 78% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $30.0, while the most cautious has a target of $3.0.

CABA operates in the Healthcare sector with a market capitalisation of $463M. The stock is up 23.5% year-to-date and is currently trading near the lower end of its 52-week range of $1.82 – $4.23.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

PALI +396.2%
Palisade Bio, Inc.
$359M · P/E 3.2x · Buy
PLX +316.7%
Protalix BioTherapeutics, Inc.
$213M · P/E 11.5x · Buy
QTTB +269.4%
Q32 Bio Inc.
$330M · P/E 3.5x · Buy
SABS +241.2%
SAB Biotherapeutics, Inc.
$310M · P/E 14.2x · Buy
XFOR +231.4%
X4 Pharmaceuticals, Inc.
$347M · P/E 2.4x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for CABA, with each firm's 90-day track record across all stocks we track. See full firm rankings →

HC Wainwright & Co. reit
Buy → Buy 2026-09-01 31% win rate (48 calls)
Wells Fargo - Reiterated
Equal-Weight → Equal-Weight 2026-08-14 Building track record
Wells Fargo - Reiterated
Equal-Weight → Equal-Weight 2026-05-15 Building track record
Cantor Fitzgerald reit
Overweight → Overweight 2026-05-04 40% win rate (10 calls)
Morgan Stanley - Reiterated
Overweight → Overweight 2026-03-24 Building track record
Guggenheim - Reiterated
Buy → Buy 2026-03-24 62% win rate (8 calls)
Cantor Fitzgerald - Reiterated
Overweight → Overweight 2025-10-31 40% win rate (10 calls)
HC Wainwright & Co. reit
Buy → Buy 2025-10-10 31% win rate (48 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
31
out of 100
Coverage depth
17/30
Consensus clarity
0/30
Vote unanimity
12/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →